Astellas wins Japanese approval for Xtandi; Ukraine conflict dents Stada forecasts;

@FiercePharma: Just out: today's full issue of FiercePharmaMarketing. More | Follow @FiercePharma

@TracyStaton: Anti-inflammatories rule! Top 3 best-selling drugs last year = Humira, Enbrel + Remicade. Report | Follow @TracyStaton

@EricPFierce: AmerisourceBergen global expansion continues with $100M deal for a 20% stake in Brazil's Profarma. Article | Follow @EricPFierce

@CarlyHFierce: AstraZeneca, Pfizer say direct-delivery programs can win with patients. Story | Follow @CarlyHFierce

> Baxter International ($BAX) has cut shipments of emergency-room staple nitroglycerin, putting it in short supply. More (sub. req.)

> Astellas has won marketing approval in Japan for its prostate cancer treatment Xtandi. Release

> Medical patch maker Corium has updated its plans to go public, saying its IPO could raise up to $76 million. More

> Japanese pharma Dainippon Sumitomo Pharma (DSP) has won approval to market its Latuda as a treatment for schizophrenia in adults. Report

> Stada sank the most in more than two years after announcing its sales and profit would be less than forecast thanks to the Russia-Ukraine conflict. More

> The FDA's Janet Woodcock is disputing research published last year that found impurities in several generic heart drugs made overseas. More

Medical Device News

@FierceMedDev: More legal action is in the mix against Intuitive over its robotic surgical device. Story | Follow @FierceMedDev

@MarkHFierce: The latest FierceDiagnostics is ready for you, featuring details on an IPO, cancer Dx and Alzheimer's biomarkers. Report | Follow @MarkHFierce

@MichaelGFierce: Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Tiny recorder helps parents communicate with children, and could spur brain development. Article | Follow @EmilyWFierce

> Did J&J intentionally destroy documents relevant to patients' vaginal mesh lawsuits? Story

> GE Healthcare will supply cancer Dx tools in new Indian care clinics. News

Biotech News

@FierceBiotech: Startup scPharmaceuticals snags $16M for self-dosed injectables. Read | Follow @FierceBiotech

@JohnCFierce: Fierce readies a new weekly report on the European biotech scene. Details | Follow @JohnCFierce

@DamianFierce: Sanofi bets big on dengue with eyes on a blockbuster. More | Follow @DamianFierce

@EmilyMFierce: Most read at yesterday: Amylin diabetes drug improves learning, memory in Alzheimer's mice. Story | Follow @EmilyMFierce

> With FDA decision looming, GlaxoSmithKline nails EU OK for diabetes drug albiglutide. News

> Insmed faces another setback as lead therapy flunks PhII lung study. Story

Drug Delivery News

> Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient. News

> Nasal spray for depression offers minimally invasive treatment option. Story

> FDA accepts Avanir's inhaled migraine treatment application. News

> Small, drug-releasing battery could dissolve completely over time. Article

> Clumps of gold nanoparticles retain heat or drugs to kill cancer cells. Story

> Alexza secures $45 million from investors based on U.S. Adasuve sales. Brief

Diagnostics News

> Ariosa Diagnostics mulls an IPO worth up to $69M. News

> Foundation Medicine seeks up to $150M to keep its cancer Dx growth engine running. Story

> CTC levels could provide a prostate cancer survival clue. Article

> Mobile app could offer inexpensive Dx in developing world. Story

> Two Alzheimer's biomarker studies spur hope for earlier-stage diagnosis. Story

> Four new biomarkers may enable an earlier stomach cancer diagnosis. Brief

Pharma Marketing News

> ASCO plans cost-benefit scorecard for cancer meds as prices grow 'unsustainable.' Story

> Pharma is a 'design industry,' expert says. So why don't all Big Pharmas have CDOs? Article

> Astellas presents The Bladder, animated pitch-organ for overactive-bladder med Myrbetriq. Story

> AstraZeneca, Pfizer say direct-delivery programs can win with patients. Article

> Great expectations: Patients think pharma owes them apps, rewards, and more. Piece

> AstraZeneca, Sanofi tap mobile providers for patient-monitoring services. Brief

And Finally... Human growth hormone--antiaging elixir or cancer and early death risk? It could be both, scientists say. Report (sub. req.)

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.